Discrete Particles In Supporting Matrix Patents (Class 424/469)
  • Publication number: 20130189356
    Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 25, 2013
    Inventor: Norbert Otterbeck
  • Patent number: 8486449
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: July 16, 2013
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8486448
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: July 16, 2013
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8475840
    Abstract: The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: July 2, 2013
    Assignee: Hanmi Science Co., Ltd
    Inventors: Jong Soo Woo, Hong-Gi Yi, Moon-Hyuk Chi, Jae-Kuk Ryu, Si-Young Jung, Yong-Il Kim
  • Patent number: 8461187
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Patent number: 8460710
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: June 11, 2013
    Assignee: Shionogi, Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Publication number: 20130108698
    Abstract: Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer comprised of polymeric composition having a Tg less than about 40° C. that substantially covers the core; and a second coating layer, which substantially covers the first coating layer, comprised of a high temperature film forming polymer. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 2, 2013
    Applicant: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
    Inventor: Johnson & Johnson Consumer Companies, Inc.
  • Patent number: 8394408
    Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: March 12, 2013
    Assignee: Depomed, Inc.
    Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
  • Patent number: 8372431
    Abstract: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: February 12, 2013
    Assignee: BIAL-Portela & C.A., S.A.
    Inventors: Teófilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
  • Patent number: 8372432
    Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: February 12, 2013
    Assignee: Depomed, Inc.
    Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
  • Patent number: 8357397
    Abstract: The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. In one of the embodiments, the invention provides a method for preparing a controlled release composition comprising the steps of: providing a mixture of a recombinant gelatin and a pharmaceutical chemically cross-linking said recombinant gelatin to obtain a three dimensional network structure.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: January 22, 2013
    Assignee: Fujifilm Manufacturing Europe B.V.
    Inventors: Jan Bastiaan Bouwstra, Marc Sutter, Sebastianus Gerardus Kluijtmans, Wilhelmus Everhardus Hennink, Wim Jiskoot
  • Patent number: 8349361
    Abstract: The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. The above objective is solved by a composition for rapid disintegrating tablets in oral cavity, wherein components (a) to (c) are contained in such manner that (a) saccharides consisting of a combination of mannitol and xylitol is 40 to 90 parts by weight; (b) the inorganic excipient is 1 to 30 parts by weight; and (c) the disintegrating agent is 5 to 40 parts by weight, provided that the total amount of (a), (b) and (c) is 100 parts by weight.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 8, 2013
    Assignee: Fuji Chemical Industry Co., Ltd.
    Inventors: Nobukazu Tanaka, Yoshiro Nagai, Hiroshi Kawaguchi, Tadashi Fukami, Terumasa Hosokawa
  • Patent number: 8343524
    Abstract: Provided are cap layer compositions and base layer compositions, providing quick and extended release of an active ingredient, respectively, when placed in water. Further provided are dual release compositions including a base composition and a cap composition. The base composition may include a plaster and an active agent, and it may further include at least one of a water-soluble binder, a non-water-soluble binder, and a lubricant. The cap composition may include a plaster and an active agent, and it may further include at least one of a disintegrating agent, a non-water-soluble binder, and a lubricant. The compositions may be heated and mixed and formed into a tablet. Further provided are methods of making the compositions. Further provided are methods of controlling or eliminating pests and methods of increasing the potability of water. The compositions are effective for controlling or eliminating pests such as mosquitoes when applied at an application site.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: January 1, 2013
    Assignee: Clarke Mosquito Control Products, Inc.
    Inventors: Michael Dean Willis, Marie Elizabeth Saunders
  • Patent number: 8337890
    Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 25, 2012
    Assignee: Tris Pharma Inc
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 8323690
    Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: December 4, 2012
    Assignee: Merrion Research III Limited
    Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
  • Patent number: 8323689
    Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: December 4, 2012
    Assignee: Merrion Research III Limited
    Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
  • Patent number: 8313774
    Abstract: The present invention relates to an oral tablet composition for pharmaceutical use, comprising (1) a particle comprising an amorphous structure and a submicron domain and (2) a pharmaceutically acceptable carrier, wherein the composition is optionally coated.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: November 20, 2012
    Assignee: Magnifica Inc.
    Inventor: David Wong
  • Patent number: 8313776
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 20, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8313775
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 20, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8303987
    Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: November 6, 2012
    Assignee: Novartis AG
    Inventors: Oskar Kalb, Stephen Valazza
  • Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Patent number: 8287903
    Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 16, 2012
    Assignee: Tris Pharma Inc
    Inventors: Ketan Mehta, Yu-Hsing Tu, Ashok Perumal
  • Patent number: 8282957
    Abstract: The present invention features a tablet including particles containing a pharmaceutically active agent, wherein the particles are coated with (a) a first film layer containing a modified release polymer; and (b) a second film layer containing (i) a first polymer, wherein the first polymer is a polymer of ethyl acrylate and methyl methacrylate and (ii) a second polymer, wherein the second polymer is a polymer of methyl acrylate, methyl methacrylate and methacrylic acid.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: October 9, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Robert Shen, Vincent Chen, Der-Yang Lee
  • Patent number: 8268352
    Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: September 18, 2012
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
  • Patent number: 8268351
    Abstract: A pharmaceutical matrix film tablet with controlled release of natural mixtures of conjugated estrogens which have been obtained from the urine of pregnant mares.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: September 18, 2012
    Assignee: Abbott Products GmbH
    Inventors: Bernd Thumbeck, Klaus Budde, Gerhard Kristen, Margit Wiards
  • Patent number: 8263125
    Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: September 11, 2012
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
  • Patent number: 8263126
    Abstract: The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: September 11, 2012
    Assignee: Ethypharm
    Inventors: Pascal Oury, Gael Lamoureux, Catherine Herry, Yann Prevost
  • Patent number: 8252330
    Abstract: In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: August 28, 2012
    Assignee: McNEIL-PPC, Inc.
    Inventors: Satish Kamath, Michael Nichols
  • Patent number: 8246996
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: August 21, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8236349
    Abstract: A pharmaceutical composition comprises multiparticulates comprising a drug, a matrix material, and swelling agent. In one aspect, the multiparticulates comprise a core comprising a drug, and a coating surrounding the core. The coating is selected from the group consisting of (i) a water-permeable, substantially drug-impermeable coating, and (ii) an anti-enteric coating.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: August 7, 2012
    Assignee: Bend Research Inc.
    Inventors: Leah Elizabeth Appel, Dwayne Thomas Friesen, Edward Dennis LaChapelle, Sanjay Konagurthu, Richard Frank Falk, Joseph P. Reo
  • Patent number: 8236345
    Abstract: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: August 7, 2012
    Assignee: SmithKline Beecham Limited
    Inventors: Karen Lewis, Nicola Jayne Lilliott, Donald Colin MacKenzie
  • Patent number: 8226981
    Abstract: A method of preparing a taste-masking oral dosage form is provided. The method includes providing a first solution comprising a pharmaceutically active ingredient and a starch, providing a second solution comprising a hydrophilic polymer and a surfactant, blending the first and second solution to form a plurality of microparticles by a granulating process, wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch, and performing a compression-molding process to form the tablet.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: July 24, 2012
    Assignee: Medical and Pharmaceutical Industry Technology and Development Center
    Inventors: Chih-Chiang Yang, Wen-Che Wang, Hui-Yu Chen
  • Publication number: 20120183612
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 19, 2012
    Applicant: Euro-Celtique S.A.
    Inventors: Bianca BRÖGMANN, Silke Mühlau, Christof Spitzley
  • Patent number: 8221777
    Abstract: Methods are provided for producing a bioscaffold from natural tissues by oxidizing a decellularized tissue to produce a bioscaffold having pores therein. The pore size and porosity is increased to better accommodate intact cells so that live cells can better infiltrate and inhabit the bioscaffold. The bioscaffold may be freeze-dried or lyophilized, sterilized and (optionally) aseptically packaged for subsequent use. A further aspect of the present invention is a bioscaffold produced by the processes described herein. Methods of treatment using the bioscaffold as a graft or as a biomedical implant for implantation are also provided. Also provided are methods of seeding a bioscaffold with mammalian cells, wherein the seeding carried out either in vitro or in vivo, and wherein a bioscaffold produced as described herein is utilized for said seeding.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 17, 2012
    Assignee: Wake Forest University Health Sciences
    Inventors: Mark E. Van Dyke, George J. Christ, Patrick W. Whitlock
  • Patent number: 8216609
    Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: July 10, 2012
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
  • Publication number: 20120164220
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 28, 2012
    Applicant: PURDUE PHARMA L.P.
    Inventor: Haiyong Hugh Huang
  • Publication number: 20120121702
    Abstract: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Pramod Sarpotdar, David W. Osborne, Gordon J. Dow
  • Patent number: 8137734
    Abstract: The present invention is directed to a method of preparing an extended release pharmaceutical composition comprising cyclobenzaprine, comprising coating inert particles with a cyclobenzaprine-containing a drug layering composition to form IR beads, then coating the IR beads with an extended-release coating to form ER beads.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: March 20, 2012
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, James M. Clevenger, Timothy Grinstead
  • Patent number: 8124124
    Abstract: A compressed tablet composition comprising: a granular component comprising a plurality of solidified melt granules of a non-steroidal anti-inflammatory drug (NSAID) having a melting point in the range 30-300° C. and incorporating a disintegrant uniformly dispersed therein; characterised in that the granules comprise a continuous phase of said non-steroidal anti-inflammatory drug and further characterised in that the tablet composition comprises silicon dioxide present in an amount of 0.05-5.0% by weight of the composition. Preferably, the composition also contains an extra-granular component comprising the silicon dioxide and a lubricant. Further preferably the NSAID is ibuprofen which has a melting point in the range 75-77° C. Optionally the melting process can be carried out in an extruder. Tablets containing advantageous processing properties and dissolution characteristics are obtained.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: February 28, 2012
    Assignee: Reckitt Benckiser Healthcare (UK) Limited
    Inventors: Robert Arthur Sherry, Tracey Jane Rhoades, Frederick Raymond Higton
  • Patent number: 8119159
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 21, 2012
    Assignee: Merrion Research III Limited
    Inventors: Kenneth Iain Cumming, Zebunissa Ramtoola, Thomas Waymond Leonard
  • Patent number: 8119163
    Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: February 21, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: John G Devane, Paul Stark, Niall M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
  • Publication number: 20120021053
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 8101205
    Abstract: The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. This invention is related to a controlled release composition comprising a cross-linked gelatin and at least one therapeutic protein wherein the ratio of the average mesh size (?) of the gelatin matrix and the average hydrodynamic radius (RH) of the therapeutic protein is smaller than 2, preferably smaller than 1.5.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: January 24, 2012
    Assignee: Fujifilm Manufacturing Europe B.V.
    Inventors: Jan Bastiaan Bouwstra, Marc Sutter, Sebastianus Gerardus Kluijtmans, Wilhelmus Everhardus Hennink, Wim Jiskoot
  • Patent number: 8092835
    Abstract: Injectable microspheres are obtained from double bond functionalized polyhydric alcohol ester by a method comprising dissolving the double bond functionalized esters in a hydrophobic organic solvent, forming an aqueous solution of stabilizer, forming an oil in water emulsion where the solution of stabilizer constitutes the continuous phase and the solution of ester constitutes the disperse phase and evaporating the organic solvent or from block copolymer of PGCLM and methoxy poly(ethylene glycol).
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: January 10, 2012
    Assignee: Cytogel Pharma, LLC
    Inventors: Daqing Wu, Chih-Chang Chu, Joseph Carozza
  • Publication number: 20110311620
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Publication number: 20110287096
    Abstract: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 24, 2011
    Applicant: ABON PHARMACEUTICALS, LLC
    Inventors: Sudhir GORUKANTI, Yanming Zu, Phanidhara Kotamraj, Karunakar Neelam, Salah U. Ahmed
  • Patent number: 8053429
    Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: November 8, 2011
    Assignee: Merrion Research III Limited
    Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
  • Publication number: 20110250269
    Abstract: A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug, matrix material, and release enhancer, wherein the mass ratio of these components is solid dispersion of the poorly soluble drug: silica nanoparticles loaded with the poorly soluble drug: matrix material: release enhancer=1: 0.5˜1.25: 0.1˜0.3: 0.1˜0.3; the said solid dispersion of the poorly soluble drug contains povidone K30, soybean lecithin, and acrylic resin IV, wherein the mass ratio of the drug and the accessory materials is poorly soluble drug: povidone K30: soybean lecithin: acrylic resin IV=1: 1-3: 0.3˜0.8: 0.2˜0.5. Compared with the existing formulations, the in vivo half life of the high-efficacy, long-acting formulation of the poorly soluble drug disclosed in this invention is 2.3˜14.8 times longer while the mean residence time (MRT) of which is 7.94˜4.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 13, 2011
    Applicant: JIANGSU UNIVERSITY
    Inventors: Ximing Xu, Jiangnan Yu, Yuan Zhu, Xia Cao
  • Patent number: 8034383
    Abstract: Injectable microspheres are obtained from double bond functionalized polyhydric alcohol ester by a method comprising dissolving the double bond functionalized esters in a hydrophobic organic solvent, forming an aqueous solution of stabilizer, forming an oil in water emulsion where the solution of stabilizer constitutes the continuous phase and the solution of ester constitutes the disperse phase and evaporating the organic solvent or from block copolymer of PGCLM and methoxy poly(ethylene glycol).
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: October 11, 2011
    Assignee: Cytogel Pharma, LLC
    Inventors: Daqing Wu, Chih-Chang Chu, Joseph Carozza
  • Patent number: 8025897
    Abstract: Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: September 27, 2011
    Assignee: McNeil-PPC, Inc.
    Inventors: Frank J. Bunick, Feng Lin